These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31958094)

  • 1. The Role of Free and Cued Selective Reminding Test in Predicting [18F]Florbetaben PET Results in Mild Cognitive Impairment and Mild Dementia.
    Spallazzi M; Michelini G; Barocco F; Dieci F; Copelli S; Messa G; Scarlattei M; Pavesi G; Ruffini L; Caffarra P
    J Alzheimers Dis; 2020; 73(4):1647-1659. PubMed ID: 31958094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Incremental Diagnostic Value of [18F]Florbetaben PET and the Pivotal Role of the Neuropsychological Assessment in Clinical Practice.
    Spallazzi M; Barocco F; Michelini G; Morelli N; Scarlattei M; Baldari G; Ruffini L; Caffarra P
    J Alzheimers Dis; 2019; 67(4):1235-1244. PubMed ID: 30689568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
    Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
    Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations Between Free and Cued Selective Reminding Test and Cerebrospinal Fluid Biomarkers in Amnestic Mild Cognitive Impairment.
    Giuffrè GM; Quaranta D; Citro S; Morganti TG; Martellacci N; Vita MG; Rossini PM; Calabresi P; Marra C
    J Alzheimers Dis; 2024; 100(2):713-723. PubMed ID: 38905044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain Metabolism Correlates of the Free and Cued Selective Reminding Test in Mild Cognitive Impairment.
    Caffarra P; Ghetti C; Ruffini L; Spallazzi M; Spotti A; Barocco F; Guzzo C; Marchi M; Gardini S
    J Alzheimers Dis; 2016; 51(1):27-31. PubMed ID: 26836012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construct validity of the Free and Cued Selective Reminding Test in older adults with memory complaints.
    Clerici F; Ghiretti R; Di Pucchio A; Pomati S; Cucumo V; Marcone A; Vanacore N; Mariani C; Cappa SF
    J Neuropsychol; 2017 Jun; 11(2):238-251. PubMed ID: 26560406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer's Disease.
    Florek L; Tiepolt S; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Luthardt J; Sattler B; Patt M; Hoffmann KT; Villringer A; Classen J; Gertz HJ; Sabri O; Barthel H
    J Alzheimers Dis; 2018; 66(3):1105-1116. PubMed ID: 30400095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Free and cued selective reminding test predicts progression to Alzheimer's disease in people with mild cognitive impairment.
    Grande G; Vanacore N; Vetrano DL; Cova I; Rizzuto D; Mayer F; Maggiore L; Ghiretti R; Cucumo V; Mariani C; Cappa SF; Pomati S
    Neurol Sci; 2018 Nov; 39(11):1867-1875. PubMed ID: 30051200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Amyloid positron-emission-tomography with [
    Schönecker S; Prix C; Raiser T; Ackl N; Wlasich E; Stenglein-Krapf G; Mille E; Brendel M; Sabri O; Patt M; Barthel H; Bartenstein P; Levin J; Rominger A; Danek A
    Nervenarzt; 2017 Feb; 88(2):156-161. PubMed ID: 27913818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TMA-93 Validation by Alzheimer's Disease Biomarkers: A Comparison with the Free and Cued Selective Reminding Test on a Biobank Sample.
    Rodrigo-Herrero S; Luque-Tirado A; Méndez-Barrio C; García-Solís D; Bernal Sánchez-Arjona M; Oropesa-Ruiz JM; Maillet D; Franco-Macías E
    J Alzheimers Dis; 2021; 82(1):401-410. PubMed ID: 34024831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The free and cued selective reminding test: Validation for mild cognitive impairment and Alzheimer's disease.
    Lemos R; Simões MR; Santiago B; Santana I
    J Neuropsychol; 2015 Sep; 9(2):242-57. PubMed ID: 24894485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between FCSRT and LASSI-L to Detect Early Stage Alzheimer's Disease.
    Matias-Guiu JA; Cabrera-Martín MN; Curiel RE; Valles-Salgado M; Rognoni T; Moreno-Ramos T; Carreras JL; Loewenstein DA; Matías-Guiu J
    J Alzheimers Dis; 2018; 61(1):103-111. PubMed ID: 29125488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
    Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
    J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Free and Cued Selective Reminding Test: Discriminative Values in a Naturalistic Cohort.
    Girtler N; Chincarini A; Brugnolo A; Doglione E; Orso B; Morbelli S; Massa F; Peira E; Biassoni E; Donniaquio A; Grisanti S; Pardini M; Arnaldi D; Nobili F
    J Alzheimers Dis; 2022; 87(2):887-899. PubMed ID: 35404273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective Reminding and Free and Cued Selective Reminding in Mild Cognitive Impairment and Alzheimer Disease.
    Lemos R; Afonso A; Martins C; Waters JH; Blanco FS; Simões MR; Santana I
    Appl Neuropsychol Adult; 2016; 23(2):85-93. PubMed ID: 26375308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of amyloid-β pathology in amnestic mild cognitive impairment with neuropsychological tests.
    Bahar-Fuchs A; Villemagne V; Ong K; Chetélat G; Lamb F; Reininger CB; Woodward M; Rowe CC
    J Alzheimers Dis; 2013; 33(2):451-62. PubMed ID: 23011220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.